Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
IRIDEX Corporation IRIX
$2.24
-$0.01 (-0.44%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
36816560.00000000
-
week52high
3.49
-
week52low
1.96
-
Revenue
56972000
-
P/E TTM
-5
-
Beta
1.25051900
-
EPS
-0.47000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Stifel | Hold | Buy | 26 авг 2022 г. |
| Roth Capital | Buy | Buy | 12 мая 2021 г. |
| Roth Capital | Buy | Buy | 03 мар 2021 г. |
| Roth Capital | Buy | Buy | 13 янв 2021 г. |
| Stifel | Buy | Buy | 12 мая 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Mercer Patrick | D | 87283 | 71 | 30 окт 2022 г. |
| Bruce David | A | 121270 | 121270 | 27 окт 2022 г. |
| Bruce David | A | 153118 | 59730 | 27 окт 2022 г. |
| Mercer Patrick | D | 72218 | 72218 | 27 окт 2022 г. |
| Mercer Patrick | A | 87354 | 35570 | 27 окт 2022 г. |
| Mercer Patrick | D | 51784 | 72 | 30 сент 2022 г. |
| Mercer Patrick | D | 51856 | 71 | 30 авг 2022 г. |
| Mercer Patrick | D | 51927 | 71 | 30 июл 2022 г. |
| Mercer Patrick | D | 51998 | 2016 | 04 июл 2022 г. |
| Bruce David | D | 93388 | 4640 | 04 июл 2022 г. |
Новостная лента
Iridex (IRIX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:47
Iridex (IRIX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.15 per share a year ago.
Iridex to Report First Quarter Financial Results on May 11, 2023
GlobeNewsWire
27 апр 2023 г. в 16:05
MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023.
IRIDEX Corporation (IRIX) Q4 2022 Earnings Call Transcript
Seeking Alpha
09 мар 2023 г. в 22:12
IRIDEX Corporation (NASDAQ:IRIX ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group David Bruce - President and CEO Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Tom Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Fourth Quarter 2022 IRIDEX Conference Call.
Iridex (IRIX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мар 2023 г. в 19:02
Iridex (IRIX) delivered earnings and revenue surprises of 36.36% and 0.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Iridex to Present at the 35th Annual Roth Conference
GlobeNewsWire
07 мар 2023 г. в 16:05
MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming 35th Annual Roth Conference in Laguna Niguel, CA.